Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its participation in two upcoming investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 19, delivering a corporate overview and holding one-on-one meetings, with a presentation scheduled for 9:10 am ET. Additionally, management will participate in the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 21, conducting one-on-one meetings. Both events will be accessible via webcast through the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – SENS
On the day this news was published, SENS declined 2.60%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GERMANTOWN, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November:
Stifel 2024 Healthcare Conference
Format: Corporate overview and one-on-one meetings
Date: Tuesday, November 19, 2024
Time: 9:10 am ET
Webcast: Click here
Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Format: One-on-one meetings
Date: Thursday, November 21, 2024
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
Investors@senseonics.com
FAQ
When is Senseonics (SENS) presenting at the Stifel 2024 Healthcare Conference?
Which investor conferences is Senseonics (SENS) attending in November 2024?
How can investors access Senseonics (SENS) conference presentations?
What type of meetings will Senseonics (SENS) hold at the Canaccord Genuity Forum?
